Dr. Philip Norman: An AAFA Tribute to an Allergy Legend

If you’ve ever benefited from immunotherapy (allergy shots, SLIT or oral immunotherapy), you can thank Dr. Philip Sidney Norman. Dr. Norman put allergy research on the map. He is known as the “father of modern immunotherapy for allergic disease” and even coined the term “allergen immunotherapy.” As an allergist and researcher for more than 50 years, he published 237 research papers and more than 100 book chapters and reviews. And for many decades, he was an important part of AAFA.

We Fight, Support and Advocate in Honor of Those Who Have Lost Their Lives

Dear Friends, One of the hardest things we do at the Asthma and Allergy Foundation of America is have conversations with families who have lost loved ones to asthma. Our hearts break for them. We grieve along with them. After hearing these stories, we are determined to do even more for people with asthma and allergies. We understand that an asthma or allergy diagnosis can be a life-changing event. For those affected, we stand together, prepared not only to listen and to empathize, but also...

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).

FDA Will Consider Xolair for the Treatment of Nasal Polyps

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.

Building and Remodeling When You Have Asthma and Allergies: Paint, Flooring and Insulation

Before you start a home building or renovation project, consider how the products you use or install may impact the overall health of your home. During construction, a lot of dust is generated and volatile organic compounds (VOCs) can be released. It’s important to consider choosing materials that emit fewer gases or other asthma triggers.

Her Health Comes First: One Mother Talks About the Challenges of Managing Her Child's Asthma

Asthma can be scary and overwhelming. It is the leading chronic disease in children and the top reason for missed school days due to chronic illness. I’m sure if you’ve been touched by this disease, you might empathize with this experience from LaJoy and her daughter, Abria.

With 10 Days Left in Marketplace Open Enrollment, AAFA Offers New Digital Tool for Instant Access to Asthma and Health Insurance Help

The Asthma and Allergy Foundation of America (AAFA) has released a new tool for the asthma community – an asthma health chatbot. The chatbot is available 24 hours a day, seven days a week to help people get answers to their questions about asthma or health insurance. This can be a valuable tool for people shopping for health insurance during the final 10 days left in the federal open enrollment period.

AAFA Meets With DOT Alongside Other Disability Advocacy Groups to Discuss Service Animal Regulations for Airlines

Today, the Asthma and Allergy Foundation (AAFA) met with the Department of Transportation alongside several disability advocacy groups. We discussed service animal regulations and the impact of growing numbers of emotional support animals on airlines. We shared how difficult it is to travel when you have asthma and/or pet dander allergy. We’re working together to ensure people are treated fairly when it comes to disability accommodations—and not privileging one disability type over another.

×
×
×
×